Emerging drugs and combination strategies for basal cell carcinoma

Expert Opinion on Emerging Drugs

Volumn 19, Issue 3, 2014, Pages 353-365

  Dreier, Jil ^a   Dummer, Reinhard ^a   Felderer, Lea ^a   Nägeli, Mirjam ^a   Gobbi, Sharon ^a   Kunstfeld, Rainer ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adverse events; Basal cell carcinoma; Combination therapy; Hedgehog inhibitors; Resistance; Side effects; Smoothened inhibitors; Sonidegib; Toxic myopathy

Indexed keywords

ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; SMO PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; HUMAN; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HEDGEHOG PROTEINS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84906812577     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.914171     Document Type: Review

References (105)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166(5):1069-80
2. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353(21):2262-9
3. Bulliard JL, Panizzon RG, Levi F. Epidemiology of epithelial skin cancers. Rev Med Suisse 2009;5(200):882-884-8
4. Dreier J, Felderer L, Barysch M, et al. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin Pharmacother 2013;14(10):1307-18
5. Walling H, Fosko S, Geraminejad P, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004;23(3-4):389-402
6. Trakatelli M, Morton CA, Nagore E, et al. Update of the Guideline on Basal Cell Carcinoma [WWW document] URL. 2012. Available from: http://www.euroderm.org/images/stories/guidelines/guideline-Basal-Cell- Carcinomaupdate2012% 20.pdf
7. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine 1987;66(2):98-113
8. Archer TC, Weeraratne SD, Pomeroy SL. Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol 2012;30(17):2154-6
9. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014;50(4):774-83
10. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146(Suppl 61):1-6
11. European-Skin-Cancer-Foundation. Basal cell carcinoma. Available from: http://www.escf-network.eu/en/patients/skin-cancer/basal-cell-carcinoma.html [Cited 15 January 2014]
12. American-Cancer-Society. Cancer Facts & Figures 2013. Atlanta; 2013. Available from: www.cancer.gov
13. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327(7418):794-8
14. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30(5 Pt 1):774-8
15. Roche-Pharma-AG. Dossier zur Nutzenbewertung gemaß § 35a SGB V; Vismodegib (Erivedge®); Modul 3 A; 2013 31.07.2013
16. Dreier J, Bogdan AI, Cheng P, Dummer R. Basal cell carcinomas in a tertiary referral centre-a systematic analysis [abstract] (Poster). World melanoma congress EADO Meeting; 17 - 20 July 2013; Hamburg, Germany
17. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;17;361(12):1173-8
18. Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg 2011;30(Suppl 4):S14-18
19. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366(23):2171-9
20. Hutchin ME, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 2005;19(2):214-23
21. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003;3(12):903-11
22. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 2002;16(21):2743-8
23. Binns W, James LF, Shupe JL, Everett G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum Californicum. Am J Vet Res 1963;24:1164-75
24. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8(10):743-54
25. Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 2004;14(2):96-102
26. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19(19):5576-81
27. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455(7211):406-10
28. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clin Cancer Res 2011;17(8):2512-20
29. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361(12):1164-72
30. Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 2012;74(5):788-96
31. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month erivance BCC Study Update. ESMO; 28 September - 2 October 2012; Vienna
32. Sekulic A MM, Oro A, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): 18-month ERIVANCE BCC study update. J Clin Oncol 2013;31(Suppl):abstract 9037
33. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366(23):2180-8
34. Grob JJ, Kunstfeld R, Dréno B, et al. et al.. Vismodegib, a Hedgehog pathway inhibitor, in advanced basal cell carcinoma: STEVIE Study interim analysis in 300 patients. ASCO meeting; 31 May - 4 June 2013; Chicago
35. Rodon J, Tawbi HA, Thomas AL, et al. A phase 1, multicenter, open-label, first-in-human, dose-escalation study of the oral Hedgehog inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014;20(7):1900-9
36. Clinical Trials.gov Identifier: NCT01327053
37. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011;131(8):1735-44
38. Peukert S, He F, Dai M, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. Chem Med Chem 2013;8(8):1261-5
39. Siu LL, Papadopoulos K, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol 2010;28(Suppl):abstract 2501
40. Bendell J, Weiss G, Infante J, et al. 594 A phase I dose-escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) evaluation of LY2940680, an oral Smo inhibitor. Eur J Cancer 2012;48(6):182
41. Goldman JW, Eckhardt SG, Borad M, et al. Phase 1 dose-escalation trial of the investigational Hedgehog (HH) pathway inhibitor TAK-441 in patients with advanced solid tumors [abstract 2739]. ESMO congress; 2012
42. Teperino R, Amann S, Bayer M, et al. Hedgehog Partial Agonism Drives Warburg-like Metabolism in Muscle and Brown Fat. Cell 2012;151(2):414-26
43. Straface G, Aprahamian T, Flex A, et al. Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med 2009;13(8b):2424-35
44. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326(5952):572-4
45. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res 2011;71(15):5057-61
46. Litwack G. Hedgehog signaling. Preface. Vitam Horm 2012;88:xxi-xxii
47. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2(51):51ra70
48. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71(2):435-44
49. Riobo NA, Lu K, Ai X, et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA 2006;Mar;21;103(12):4505-10
50. Hafner C, Landthaler M, Vogt T. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Exp Dermatol 2010;19(8):e222-e7
51. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10(3):143-53
52. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013;10(4):191-210
53. Clinical Trials.gov Identifier: NCT01576666. Available from: www.clinicaltrials.gov
54. Mimeault M, Johansson SL, Vankatraman G, et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007;6(3):967-78
55. Schnidar H, Eberl M, Klingler S, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009;69(4):1284-92
56. Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012;4(3):218-33
57. Palmer SR, Erlichman C, Fernandez-Zapico M, et al. Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. J Clin Oncol 2011;29(Suppl):abstract 3092
58. Krähn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001;37(2):251-9
59. Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008;39(3):344-9
60. Lewis CM, Glisson BS, Feng L, et al. A phase II study of Gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18(5):1435-46
61. Sonkoly E, Loven J, Xu N, et al. MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Oncogenesis 2012;1:e3
62. Sand M, Skrygan M, Sand D, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res 2013;351(1):85-98
63. Heffelfinger C, Ouyang Z, Engberg A, et al. Correlation of global microRNA expression with basal cell carcinoma subtype. G3 (Bethesda) 2012;2(2):279-86
64. Bigelow RLH, Chari NS, Undén AB, et al. Transcriptional regulation of bcl-2 mediated by the sonic Hedgehog signaling pathway through gli-1. J Biol Chem 2004;279(2):1197-205
65. Delehedde M, Cho SH, Sarkiss M, et al. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer 1999;85(7):1514-22
66. Rodriguez-Villanueva J, Colome MI, Brisbay S, McDonnell TJ. The expression and localization of bcl-2 protein in normal skin and in nonmelanoma skin cancers. Pathol Res Pract 1995;191(5):391-8
67. Smoller BR, Van De Rijn M, Lebrun D, Warnke RA. BCL-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol 1994;131(1):28-31
68. Regl G, Kasper M, Schnidar H, et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 2004;64(21):7724-31
69. Chen X-l, Cheng Q-y, She M-r, et al. Expression of sonic Hedgehog signaling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro. Arch Med Res 2010;41(5):315-23
70. Matthews J. Bcl-2 Inhibitors. In: Roberts GK, editor. Encyclopedia of biophysics. Springer; Berlin Heidelberg: 2013. p. 184
71. Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27(Suppl 1):S149-57
72. Oakes SR, Vaillant F, Lim E, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci 2012;109(8):2766-71
73. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10(5):389-99
74. Mason KD, Khaw SL, Rayeroux KC, et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009;23(11):2034-41
75. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;2;435(7042): 677-81
76. Kunkalla K, Liu Y, Qu C, et al. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol 2013;92(6):777-87
77. Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol 2006;16(5):543-7
78. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7(7a):1126-32
79. Zhao Y, Yu S, Sun W, et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 2013;56(13):5553-61
80. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol 2010;3(1):1-12
81. Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53(12):2736-9
82. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55(1):96-107
83. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H. A. Clowes Memorial Award Lecture. Cancer Res 1999;Jan;1;59(1):1-7
84. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-31
85. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10(12):1321-8
86. Grinkevich VV, Nikulenkov F, Shi Y, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009;15(5):441-53
87. Krajewski M, Ozdowy P, D'Silva L, et al. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 2005;11(11):1135-6; author reply 6-7
88. NCI Drug Dictionary: p53/HDM2 interaction inhibitor CGM097. Available from: www.cancer.gov/drugdictionary
89. Clinical Trials.gov Identifier: NCT01760525. Available from: www.clinicaltrials.gov
90. Kim J, Tang JY, Gong R, et al. Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth. Cancer Cell 2010;17(4):388-99
91. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014;32:(8):745-51
92. Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci 2010;107(30):13432-7
93. Xia J, Li Y, Yang Q, et al. Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci 2012;13(8):9627-41
94. Clinical Trials.gov Identifier: NCT01791894
95. Kim J, Aftab Blake T, Tang Jean Y, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013;23(1):23-34
96. Karagas MR, Stukel TA, Morris JS, et al. Skin cancer risk in relation to Toenail arsenic concentrations in a US population-based Case-Control Study. Am J Epidemiol 2001;153(6):559-65
97. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer. Cancer 2002;94(2):477-85
98. Kim KH, Yavel RM, Gross VL, Brody N. Intralesional interferon α-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004;30(1):116-20
99. Buechner SA. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 1991;24(5 Pt 1):731-4
100. Buechner S, Wernli M, Bachmann F, et al. Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer Res 2002;160:246-50
101. Li C, Chi S, He N, et al. IFN[alpha] induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 2003;23(8):1608-17
102. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139(10):1325-32
103. Wolff F, Loipetzberger A, Gruber W, et al. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene 2013;32(50):5574-81
104. Makinodan E, Marneros AG. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin. Exp Dermatol 2012;21(11):847-52
105. Walter A, Barysch MJ, Behnke S, et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res 2010;16(14):3562-70